A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
about
Targeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei.Stereospecific Effects of Oxygen-to-Sulfur Substitution in DNA Phosphate on Ion Pair Dynamics and Protein-DNA AffinityNanoparticulate carriers for the treatment of coronary restenosisCharacterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization.The p53 tumor suppressor gene is regulated in vivo by nuclear factor 1-C2 in the mouse mammary gland during pregnancyDifferences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cellsUAP56 is an important mediator of angiotensin II/platelet derived growth factor induced vascular smooth muscle cell DNA synthesis and proliferationThe heat shock paradox and cardiac myocytes: role of heat shock factorInhibition of E2F abrogates the development of cardiac myocyte hypertrophyNeointimal hyperplasia associated with synthetic hemodialysis grafts.Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity.Effective transfection of a cis element "decoy" of the nuclear factor-kappaB binding site into the experimental choroidal neovascularization.Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach.c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3Gene therapy for kidney disease.Therapeutic applications of transcription factor decoy oligonucleotidesThe role of preexisting pathology in the development of neointimal hyperplasia in coronary artery bypass graftsSmall RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?Local gene delivery to the vessel wall.Restenosis and gene therapy.Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?BCR-ABL as a target for novel therapeutic interventions.Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.Gene therapy for cerebral vascular disease: update 2003.Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.Applied gene therapy in preclinical models of vascular injury.Vascular complications and gene therapy.Targeting the cell cycle machinery for the treatment of cardiovascular disease.Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases.Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosisRegulatable aptamers in medicine: focus on antithrombotic strategies.Cardiovascular gene delivery: The good road is awaitingDistinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.Cardiovascular gene therapy: current status and therapeutic potential.Suppression of activation of signal transducer and activator of transcription-5B signaling in the vessel wall reduces balloon injury-induced neointima formation.Gene therapy for the extension of vein graft patency: a review.Does gene therapy become pharmacotherapy?The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.Manipulating and understanding antibiotic production in Streptomyces coelicolor A3(2) with decoy oligonucleotides.
P2860
Q24810050-875040F9-F0F3-4E55-8565-3EB562A1971FQ27708987-7CB85778-0C15-4899-B076-8104C0722C8FQ28220309-5E13A79F-C4C6-44DA-94AB-C1AF6EBA891EQ28504628-0E1A9242-6553-439F-93A8-97FBE4CD5CB8Q28505048-80C00A60-4CE5-4187-8067-0E335A1B3812Q28566102-C188D237-1C49-4B8A-8F3E-6EB8A2922ECAQ28571027-A884E164-024D-4F1B-BB53-1EF2D91EC01BQ28573567-A79534D3-C300-4ACB-BADF-958AC3712A08Q28576514-09CEF0A9-751A-4D37-846A-FEBD137CB4FAQ30492883-A35B2AB8-8D70-4B63-A189-2A44B05CC17EQ30752077-F7FC0AAD-8EAA-4AB9-89A5-A13DA935BA65Q33185693-F5C91DD7-9001-46F7-99D1-06C958FA3563Q33598723-388EE1D9-383E-4334-8CDB-FDEB0E7D491CQ33662275-50FEF9D5-E189-4893-9BE7-D544C5E0FC51Q34046503-97E53A0B-BBE9-4FBD-B843-884BD0BD63ADQ34074844-14326CBE-94BB-49AE-AA8A-58BD4D66FA2CQ34078075-F4533D95-E1E8-499F-B339-76D10000CA62Q34096919-17AFDE20-3FA2-4B67-AFDC-14464D07C09BQ34405044-A13DFF43-E581-430E-83E1-5284F6CE9328Q34418987-0D11A037-F2EB-4875-87F5-51C4C7C888FCQ34452138-D214BCE2-9BCB-47D6-8741-B77EEE2208F3Q34482530-A175DE2B-428F-4851-B013-9A94B0193B63Q34568971-FC22FAC6-7945-490C-B1B0-D347506B38A9Q34984257-F9078D60-20A6-424E-AEAF-97334AA674C9Q35045240-BC37CF58-81DB-4D47-950C-898F11C2A387Q35046229-D300C692-19A1-4BC7-8FEA-EAEA1213D7E6Q35095408-26F066E2-FFA5-4B0A-8B87-1AC6DEF7F193Q35116151-D7FF513C-0C76-430F-99EE-65E9B5C11E48Q35164884-16BA3781-3C83-42E2-B6B8-B88E7C71BFD7Q35696375-D89AC6BD-DC0E-4CF9-BC0D-9F1FF9B9D025Q35723980-83E769DC-521C-4E54-8272-775818EEF5CBQ35907032-9CDADF16-D40B-4C99-A192-27C96DCBEE1BQ35915765-057E062D-AFEA-486B-9429-2DBBE70B5261Q35928855-7EB76710-F2A0-4E8B-B04E-FAF140D7C507Q35995220-CC174540-9FF2-4653-B0B9-94CD16B39C77Q36007499-61148709-CBC4-4BD5-99E8-E195C694BA09Q36032833-78DCDE0E-B184-4E32-A376-E5A04E14475BQ36075155-40B344E3-DE94-4107-B1A1-1170F3CC6F41Q36405134-9868DA2C-F85D-4791-8A10-8F7A2E281EE5Q36458851-485A670C-CFB6-4AAC-B8DE-73800E3C36EA
P2860
A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
A gene therapy strategy using ...... muscle proliferation in vivo.
@ast
A gene therapy strategy using ...... muscle proliferation in vivo.
@en
A gene therapy strategy using ...... muscle proliferation in vivo.
@nl
type
label
A gene therapy strategy using ...... muscle proliferation in vivo.
@ast
A gene therapy strategy using ...... muscle proliferation in vivo.
@en
A gene therapy strategy using ...... muscle proliferation in vivo.
@nl
prefLabel
A gene therapy strategy using ...... muscle proliferation in vivo.
@ast
A gene therapy strategy using ...... muscle proliferation in vivo.
@en
A gene therapy strategy using ...... muscle proliferation in vivo.
@nl
P2093
P2860
P356
P1476
A gene therapy strategy using ...... muscle proliferation in vivo.
@en
P2093
G H Gibbons
K E Ellison
M Horiuchi
R Morishita
P2860
P304
P356
10.1073/PNAS.92.13.5855
P407
P577
1995-06-01T00:00:00Z